Some studies have also identified MTH1 inhibitors with similar or even lower IC50 [13, 25] which either caused cytotoxic effects regarded as MTH1 independent or had no significant impact on cell viability thus challenging the concept of MTH1 inhibition as an anti-tumor strategy. The gene discussed is NUDT1; the disease is neoplasm.